Advanced Prostate Cancer COE

Influence of BRCA-2 Mutations on the Natural History and Response to Therapy in Prostate Cancer- Elena Castro

Elena Castro, MD discusses the role of BRCA-2 mutations and the risk of developing prostate cancer. BRCA-2 germline carriers have an increased risk of developing prostate cancer representing a ~30% lifetime rate of developing prostate cancer. Patients with BRCA-2 mutations tend to develop more aggressive prostate cancer and typically present with lymph node involvement or distant metastases. Based...

Disruptive Technologies in Radiology & Nuclear Medicine - Phillip Koo

Phillip Koo and Alicia Morgans discuss disruptive changes impacting clinical practice. Clearly, medical practice disruptions occur more incrementally than when we think of what this means in consumer-based areas and yet each day new data from key clinical trials has the potential to shake up what is viewed-as the current standard of care. New data is challenging radiology and nuclear medicine as w...

Challenges in the Treatment of Localized Prostate Cancer - Srikala Sridhar

Kala Sridhar and Alicia Morgans share in a discussion on challenges and opportunities in the treatment of localized prostate cancer from the viewpoint of a medical oncologist. Conversation includes approaches for optimizing systemic therapy in localized disease and new hormonal agents, and the ICECAP initiative. Biographies: Srikala (Kala) Sridhar MD, MSc, FRCPC Medical Advisory and Research Board...

Diagnostic Performance of 68Ga PSMA PET CT to Detect Significant Prostate Cancer and Comparison with 18F Choline PET CT - Manuela Hoffmann

Radiolabeled prostate-specific membrane antigen (PSMA) has proven as a highly accurate method to detect recurrences and metastases of prostate cancer, but there are only sparse data about its diagnostic performance in primary prostate cancer. Manuela Hoffman presents a retrospective study of the diagnostic performance of 68Ga-PSMA PET/CT to detect significant prostate cancer in comparison with 18F...

Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus ADT for Men with Advanced Prostate Cancer - Tom Keane

(Length of video: 9 min) Tom Keane reviews an article entitled, “Comparative Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus Androgen Deprivation Therapy for Men with Advanced Prostate Cancer”. Men with locally advanced prostate cancer or regionally advanced prostate cancer treated initially with radical prostatectomy plus radiation had a lower risk of pr...

ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle Burgess

(Length of Discussion: 12 min) Alicia Morgans and Earle Burgess discuss the details of the investigator-initiated trial called ENZADA. They discuss the “why” behind the design of this Phase II trial. Their desire is to understand whether or not triplicate therapy with ADT, plus docetaxel, plus a next gen endocrine agent will further improve outcome over either agent alone in this patient populatio...

TRIUMPH Study: Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations - Mark Markowski

(Length of Discussion: 12 min) Alicia Morgans discusses with Mark Markowski details of the TRIUMPH trial, a single-arm, phase II trial, open-label using a PARP inhibitor rucaparib, in the absence of androgen deprivation therapy in men with metastatic hormone-naive prostate cancer. Biographies: Mark Christopher Markowski, MD., Ph.D., is a medical oncologist at the Kimmel Cancer Center at Sibley Mem...

Genetic Screening for Patients with Prostate Cancer - Todd Morgan

(Length of Discussion: 13 min) Todd Morgan shares the unique program that he and his GU team at the University of Michigan have implemented in an effort to gain a better understanding of the genetics and genomics involved with progression in prostate cancer. Biographies: Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies and an Associate Profes...

IRONMAN Registry: A Global Landmark Trial in Advanced Prostate Cancer

(Length of Discussion: 22 min) Alicia Morgans has a discussion with Dan George uncovering details about the IRONMAN Registry. The objective is to look globally at advanced prostate cancer, both with the metastatic and the castrate-resistant populations, seeking to understand patient outcomes and their experiences through this process. Biographies: Daniel George, MD Alicia Morgans, MD, MPH Related...

Prostate Cancer Awareness Month - David Penson

(Length of Discussion: 20 min) Alicia Morgans and David Penson discuss the relevance of Prostate Cancer Awareness Month and the importance of elevating the awareness for men and their respective caregivers about prostate cancer and other men's health issues and the need to be screened routinely for prostate cancer. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.